Table 2.

Univariate and multivariate analysis for the primary and secondary endpoints

	Events
	Primary endpoint		Secondary endpoint
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
Univariate analysis
IBD present	0.47 (0.17–1.30)	0.16	0.40 (0.12–1.28)	0.13
UDCA use	0.60 (0.23–1.55)	0.28	0.41 (0.14–1.22)	0.10
Mayo risk score at diagnosis	2.09 (1.55–2.82)	< 0.001	2.95 (1.81–4.81)	< 0.001
MELD score at diagnosis	1.22 (1.11–1.36)	< 0.001	1.32 (1.15–1.53)	< 0.001
PREsTo at diagnosis	1.05 (1.03–1.08)	< 0.001	1.03 (1.01–1.05)	< 0.001
Platelets at diagnosis, per 100	1.00 (0.99–1.00)	0.16	0.60 (0.35–1.03)	0.07
Age at diagnosis, per 5 years	1.40 (1.21–1.62)	< 0.01	1.46 (1.23–1.74)	< 0.01
Normal SAP at diagnosis	0.38 (0.05–2.82)	0.27	0.52 (0.07–4.09)	0.46
SAP < 1.5 ULN at diagnosis	0.64 (0.23–1.73)	0.37	0.70 (0.0.24–2.10)	0.52
Normal SAP (time dependent)	0.80 (0.24–2.63)	0.71	0.95 (0.29–3.16)	0.93
SAP < 1.5 × ULN (time dependent)	0.11 (0.03–0.42)	< 0.01	0.03 (0.00–0.56)	0.02
Multivariate analysis
SAP < 1.5 × ULN (time dependent)	0.10 (0.02–0.45)	0.01	0.05 (0.00–1.01)	0.05
Mayo PSC risk score	2.29 (1.59–3.30)	< 0.01	2.59 (1.56–4.29)	< 0.01
SAP < 1.5 × ULN (time dependent)	0.10 (0.02–0.39)	0.01	0.04 (0.00–0.75)	0.03
MELD score at diagnosis	1.25 (1.11–1.41)	0.01	1.29 (1.10–1.50)	< 0.01
SAP < 1.5 × ULN (time dependent)	0.16 (0.04–0.65)	0.01	0.02 (0.001–1.11)	0.06
PREsTo at diagnosis	1.05 (1.03–1.07)	< 0.001	1.02 (1.00–1.04)	0.08
SAP < 1.5 × ULN (time dependent)	0.19 (0.05–0.72)	0.01	0.05 (0.00–0.97)	0.048
Age at diagnosis	1.32 (1.14–1.52)	< 0.01	1.37 (1.16–1.62)	< 0.01

Primary endpoint = death, liver transplantation, hepatic decompensation or cholangiocarcinoma

Secondary endpoint = liver transplantation or death

IBD inflammatory bowel disease, UDCA ursodeoxycholic acid, SAP serum alkaline phosphatase, ULN upper limit of normal, MELD model for end-stage liver disease, PRETo PSC risk estimate tool